|
|
||||||||
Articles |
, and Second Messengers1
a Institute of Medical Biochemistry,
b Departments of Tumor Biology and Oncology, Norwegian Radium Hospital,
c Andrology Laboratory, Department of Gynecology and Obstetrics, National Hospital, University of Oslo, N-0317 Oslo, Norway
In the testis, FSH has been shown to induce the expression and secretion of tissue inhibitor of metalloproteinases-1 (TIMP-1) from Sertoli cells in vitro. This study was performed to elucidate further the cellular origin of testicular TIMP-1 and its expression by hormonal and paracrine factors. This is the first report on the expression of testicular TIMP-1 in vivo. TIMP-1 mRNA in whole testis was decreased after hypophysectomy and strongly increased by the injection of FSH-S17 to hypophysectomized rats. Primary cultures of both peritubular and Sertoli cells showed basal expression of TIMP-1 mRNA. In contrast, we were unable to detect TIMP-1 mRNA in Leydig cells, freshly isolated immature germ cells (primary spermatocytes and spermatids), or residual bodies. We further show that treatment of Sertoli cells with 8-(4-chlorophenyl)thio-cAMP (8-CPTcAMP) in combination with 12-O-tetradecanoylphorbol 13-acetate (TPA) or Ca2+ inducers (calcium ionophore A23187 or thapsigargin) had additive (TPA) and synergistic effects (Ca2+) on the level of TIMP-1 mRNA and secreted protein. We also show that both the level of TIMP-1 mRNA and secreted protein from Sertoli cells were strongly increased by residual bodies, as well as by the cytokine interleukin-1
. TIMP-1 was not up-regulated by either 8-CPTcAMP or interleukin-1
in peritubular cells. In contrast to the regulated secretory fraction of TIMP-1, we also detected constitutively expressed immunoreactive TIMP-1 in the nucleus of Sertoli cells, suggesting a role of nuclear TIMP-1 in these cells. In conclusion, our data show that secretion of TIMP-1 from Sertoli cells is highly regulated by hormonal and local processes in the testis, indicating that TIMP-1 is of physiological importance during both testicular development and spermatogenesis.
1 This work was supported by the Norwegian Research Council, the Norwegian Cancer Society, Novo Nordisk Foundation Committee, and Anders Jahres Foundation for the Promotion of Science.
2 Correspondence: Line M. Grønning, Institute of Medical Biochemistry, University of Oslo, P.O. Box 1112, Blindern, N-0317 Oslo, Norway. FAX: 47 22851497; l.m.gronning{at}basalmed.uio.no
3 Current address: Jacob E. Wang, Institute of Surgical Research, National Hospital, University of Oslo, N-0027 Oslo, Norway.
This article has been cited by other articles:
![]() |
P.-L. Yao, Y.-C. Lin, and J. H. Richburg TNF Alpha-Mediated Disruption of Spermatogenesis in Response to Sertoli Cell Injury in Rodents Is Partially Regulated by MMP2 Biol Reprod, March 1, 2009; 80(3): 581 - 589. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Mruk and C. Y. Cheng Sertoli-Sertoli and Sertoli-Germ Cell Interactions and Their Significance in Germ Cell Movement in the Seminiferous Epithelium during Spermatogenesis Endocr. Rev., October 1, 2004; 25(5): 747 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K.Y. Siu and C. Y. Cheng Extracellular Matrix: Recent Advances on Its Role in Junction Dynamics in the Seminiferous Epithelium During Spermatogenesis Biol Reprod, August 1, 2004; 71(2): 375 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Mruk, M. K.Y. Siu, A. M. Conway, N. P.Y. Lee, A. S.N. Lau, and C. Y. Cheng Role of Tissue Inhibitor of Metalloproteases-1 in Junction Dynamics in the Testis J Androl, July 1, 2003; 24(4): 510 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Haro and R. Janknecht Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter Nucleic Acids Res., July 1, 2002; 30(13): 2972 - 2979. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Gronning, A. Cederberg, N. Miura, S. Enerback, and K. Tasken Insulin and TNF{alpha} Induce Expression of the Forkhead Transcription Factor Gene Foxc2 in 3T3-L1 Adipocytes via PI3K and ERK 1/2-Dependent Pathways Mol. Endocrinol., April 1, 2002; 16(4): 873 - 883. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |